TABLE 3.

Votes on Other Benefits and Contextual Considerations for Lovo-cel and Exa-cel

When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for SCD, on the basis of the following contextual considerations:
Contextual consideration	Very low priority	Low priority	Average priority	High priority	Very high priority
Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability	0	2	3	4	5
Magnitude of the lifetime impact on individual patients of the condition being treated	0	0	0	1	13
What are the relative effects of exa-cel/lovo-cel vs standard of care on the following outcomes that inform judgments of the overall long-term value for money of lovo-cel/exa-cel?
Potential other benefit or disadvantage	Major negative effect	Minor negative effect	No difference	Minor positive effect	Major positive effect
Patients’ ability to achieve major life goals related to education, work, or family life	0	0	0	0	14
Caregivers’ quality of life and/or ability to achieve major life goals related to education, work, or family life	0	0	0	2	12
Patients’ ability to manage and sustain treatment given the complexity of regimen	0	0	0	4	10
Society’s goal of reducing health inequities	0	0	0	4	10

exa-cel = exagamglogene autotemcel; Lovo-cel = lovotibeglogene autotemcel; SCD = sickle cell disease.